谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non-small cell lung cancer.

Yuankai Shi,Jianhua Chen,Helong Zhang,Zhihong Zhang,Yiping Zhang,Zhehai Wang,Shucai Zhang,Jian Zhao,Chunling Liu,Xiuwen Wang,Yanqiu Zhao,Changlu Hu,Lei Yang,Xuezhi Hao,Lin Wang,Meimei Si,Mingjing Ge,Huaize Geng

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 2|浏览9
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要